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patient management as BRAF-and MEK-targeted therapies have led to improved survival and been approved as standard of care for treatment of advanced V600-mutant melanoma (Larkin et al., 2014; Long et al., 2015; Robert, Karaszewska, et al., 2015) . Immune therapy has also become an essential part of the treatment of this disease with CTLA-4 and PD1 inhibitors leading to improvements in patient survival (Larkin, Hodi, & Wolchok, 2015; Robert et al., 2011; . Individualized treatment plans using these drugs require monitoring of the patient's disease status with repeat response assessments, often over a lengthy treatment regimen.
However, repeat biopsy of multiple melanoma tumor sites for patients with advanced metastatic disease is impractical, and the addition of peripheral blood assays, so-called liquid biopsies, of tumor activity and molecular alterations may more accurately represent the disease status and full molecular spectrum of the patient's disease.
Liquid biopsy is increasingly utilized for non-invasive patient monitoring through blood samples which can contain circulating tumor cells (CTCs), cell-free circulating tumor DNA (cfDNA), and other material shed from primary and metastatic tumors. Enumeration of CTCs and monitoring of changes in CTC counts have been shown to be prognostic in multiple solid tumors (Cohen et al., 2009; Krebs et al., 2011; Riethdorf et al., 2007) ; however, commercially available approaches for melanoma CTC detection have low sensitivity, even among therapy-naïve patients (Khoja et al., 2013; Rao et al., 2011) . A more recently developed microfluidic approach showed improved sensitivity of CTC detection in melanoma patient samples, but the device is not commercially available (Luo et al., 2014) . cfDNA has traditionally been utilized for the detection of clinically actionable driver and resistance mutations and is readily detectable in the blood of patients with melanoma prior to receiving therapy (Gonzalez-Cao et al., 2015; Kaisaki et al., 2016; Knol et al., 2016; Lipson et al., 2014; Pinzani et al., 2011) . Indeed, detection of a BRAF V600 mutation is significantly associated with lower overall survival (Gonzalez-Cao et al., 2015; Knol et al., 2016) , and PCR-based approaches have been used to detect a limited number of variants in BRAF and NRAS known to be associated with resistance to BRAF and MEK inhibitors, but with very limited application to patients with melanoma after the advent of therapy (Girotti et al., 2016; Gray et al., 2015; Schreuer et al., 2016; Tsao et al., 2015; Xi et al., 2016) .
Moreover, monitoring of resistance mutations to targeted therapies is becoming increasingly complex, with multiple mutations in the MAPK and PI3K-PTEN-AKT pathways having been identified (Shi et al., 2014) . Transcriptional alterations associated with therapy resistance have also been reported (Hugo et al., 2015) ; however, circulating RNA cannot yet be as reliably detected as cfDNA. Nevertheless, the mutational complexity of therapy resistance suggests that PCR-based interrogation of a limited number of mutations may fail to detect molecular resistance to targeted therapy. To our knowledge, no study has yet prospectively evaluated whether broad coverage ultra-deep sequencing of plasma DNA can be used to comprehensively monitor molecular alterations in patients with advanced melanoma who are currently receiving or have received multiple therapies.
Cell-free DNA concentration, independent of the identification of specific mutations, has also been shown to have prognostic value (Cargnin, Canonico, Genazzani, & Terrazzino, 2017; Thompson et al., 2016) , although this has not yet been measured in melanoma. Plasma cfDNA yields for patients with lung and breast cancer have been associated with a worse prognosis (Couraud et al., 2014; Dawson et al., 2013; Thompson et al., 2016) , and changes in cfDNA levels can precede clinical and radiographic tumor regression or progression, thus allowing for real-time, non-invasive surveillance of tumor burden (Lipson et al., 2014) . Pretreatment melanoma solid tumor burden, as measured by imaging, was recently shown to be correlated with clinical response to pembrolizumab . This underscores the need to determine whether cfDNA concentration correlates with solid tumor burden, especially in melanoma and other cancers for which checkpoint inhibitors are routinely used.
Here we apply a minimally adapted, commercially available workflow for measuring cell-free DNA concentration, and ultra-deep sequencing of a panel of 61 genes in the cfDNA captured from patient plasma. We focus here on a cohort of melanoma patients with advanced disease, the majority of whom have received one or more therapies or are receiving therapy at the time of their blood draw.
| RESULTS

| Overview of patient population
In this study, we sought to explore the feasibility of using a liquid biopsy to measure cfDNA from the plasma of patients with advanced melanoma, with a focus on those who were undergoing or had previously undergone therapy. Blood was obtained from 28 patients with melanoma, cfDNA extracted, concentration measured, libraries prepared, and sequencing conducted using a 61-gene panel (Table S1 ). Results for three patients were excluded from further analysis because identified mutations did not meet our previously validated variant calling criteria (see Methods) (Janku et al., 2017) . As summarized in or nivolumab, at some point in their course of treatment. Six patients received a BRAF inhibitor and/or a MEK inhibitor prior to blood draw.
| Cell-free DNA concentration correlates with solid tumor volume
We first sought to assess whether measurement of the concentration of DNA extracted from patient plasma samples was correlated with solid tumor volume. Measurement of cfDNA was achieved for all 25 patients, with the concentration ranging from 0.6 to 390.0 ng/ml (median = 7.8 ng/ml; Figure 1a ). To measure solid tumor burden, we conducted a retrospective chart review of CT or PET imaging and included results for the 15 patients who had imaging conducted within 1 month of blood draw. We then calculated tumor burden using a modification of RECIST 1.1 (Eisenhauer et al., 2009) The denominator for this % calculation is the n = 25 total patients included in this Table. b The denominator for this % calculation varies row by row. It is the number of total patients shown in the left-most column for that row's patient category.
lesions were added together, rather than limiting the number of lesions included per organ . Using this approach, the number of lesions measured per patient ranged from 1 to 12, the size of individual lesions ranged from 1.0 cm to 18.1 cm, and when all measurable lesions were summed for each patient, the total tumor burden per patient ranged from 0.6 cm to 48.5 cm (detailed measurements shown in Table S2 ). We then compared cfDNA concentration and solid tumor volume, using Spearman rank calculation rather than Pearson's correlation, as the cfDNA yield data were determined by Shapiro-Wilk test to be non-normally distributed. As shown in Figure 1b , for the 15 patients for whom tumor burden could be calculated, the Spearman rank calculation was significant (Spearman rho = 0.5435, p = .0363), suggesting a direct correlation between liquid biopsy-and imaging-based measurement of tumor burden. A similar comparison of cfDNA yield and serum LDH, a standard of care blood test that is prognostic in melanoma (Balch et al., 2009) , was conducted but this was not significant (Spearman rho = 0.3433, p = .0929; Fig. S1 ). However, this analysis may have been confounded by the heterogeneity of therapies received by patients at time of blood draw (detail in Table S2 ).
| Mutation detection by liquid biopsy
We next sought to determine whether mutational tumor profiling could be achieved using ultra-deep sequencing of plasma cfDNA.
Although 17 of 25 patients (68.0%) were receiving one or more therapies at the time of blood draw, sufficient input DNA (>2 ng)
for next-generation sequencing (NGS) was extracted from 1 to 4 ml plasma for all 25 patients (median = 28.4 ng, range 2.4-1560.0 ng; Table S3 ). Sixteen total mutations were detected in the cfDNA of 12 out of 25 patients (48.0%), and this proportion did not vary significantly based on differences in disease state at the time of blood draw or the number or type of prior therapies (Table 1) . While others have reported low ctDNA levels for melanoma patients with subcutaneous and brain metastases (Wong et al., 2017) , (metastatic sites for our patients listed in Table S2 ), our study was not designed to assess the link between metastatic site and ctDNA level. Just as has been reported in other studies using NGS to detect variants in cfDNA (Chabon et al., 2016; Thompson et al., 2016) 
| Comparison of plasma and tissue NGS
Although our study was not designed to compare plasma and tissue NGS, it was determined during chart review that 22 of 25 patients had clinical tissue NGS conducted from 1.8 to 53.5 months prior to the liquid biopsy (detailed results shown in Table S4 ). Despite the gap in time between tissue and plasma collection, we reasoned that mutations detected in plasma DNA would likely reflect the mutational profile originally detected in tissue. As shown in Figure 3a , there were 10 patients with tissue NGS results for whom one or more mutations were detected in plasma. All 10 patients received one or more therapies in between F I G U R E 1 Measurement of cfDNA yield and correlation with tumor burden. Blood was obtained in Streck DNA BCT tubes for 25 patients with advanced melanoma, plasma processed within 36 hr of blood draw, and cfDNA extracted. Shown are the (a) cfDNA yield per ml of plasma (horizontal line indicates median = 7.8 ng/ml, range 0.6-390.0 ng/ml), and the (b) relationship between cfDNA concentration and tumor burden, calculated as the sum of the long diameter of all measurable lesions as detected by imaging at the timepoint closest to blood draw, with not more than one month elapsing between imaging and blood draw. Shown are the results for the 15 patients for whom tumor burden could be measured tissue and plasma testing (detailed treatment history shown in Table S4 ).
For this group, 13 mutations were detected in the plasma, 11 of which were covered by the tissue NGS panel. Of these 11 mutations, nine were detected in matched tissue, for a concordance of 81.8%. When the concordance calculation for these 10 patients includes four mutations that were detected in tissue but not plasma, the concordance drops to nine out of 15 mutations or 60.0%. For the two patients for whom a mutation was detected in plasma but not tissue (NRAS Q61K for patient 423, and PIK3CA R93W for patient 1368), we examined the tissue sequencing raw data and detected the mutation in a proportion of the total reads that was below the validated 4.0% level of detection (LOD) of the tissue NGS panel. For the 12 patients with tissue NGS results for whom no mutations were detected in plasma, 17 mutations were found in the tissue.
Ten of these patients received one or more therapies in between tissue and plasma testing, and three had no evidence of disease by imaging at the time of their blood draw.
| Comparison of tumor burden and sensitivity of mutation detection in plasma
Given the wide range in imaging-determined total tumor volume for our patients, we reasoned that variation in tumor burden might affect our ability to detect somatic mutations in DNA shed into plasma.
To address this, we next compared tumor volume with mutations detected in plasma DNA for each of the 15 patients for whom tumor burden could be measured within 1 month of blood draw ( Figure 3a , Table S2 ). As shown in Figure 3b , the median tumor burden for patients with no detectable mutations was 1.4 cm (range 0-4.9 cm) as compared to 16.9 cm (range 8.1-48.5 cm) for patients with one or more detectable mutations (p = .0011). No mutations were found in the plasma of any patients with a total tumor burden (the sum of all measurable lesions) of ≤4.9 cm. Among the 15 patients for whom tumor burden could be measured, 13 patients had tissue NGS F I G U R E 3 Comparison of tumor burden as measured by imaging to mutations detected in cfDNA. (a) The black bars depict the total tumor burden (in cm) for each patient as measured by imaging conducted within one month of blood draw (see detailed measurements in Table S2 ). The three patients whose numbers are bolded and underlined, 939, 940, and 1,747, were determined by imaging to have no evidence of disease. An "X" indicates that tumor burden for that patient was not assessable within one month of blood draw. This was the case for 10 patients. Immediately below the bar chart, checkmarks indicate the 22 patients for whom tissue NGS was conducted. Below the check marks is a grid detailing all mutations detected for each of the 25 patients with plasma testing. Three of the NRAS mutations were Q61K, and the fourth was Q61R. The number of mutations detected per patient ranged from zero (depicted by all white squares) to two, with detected mutations depicted in gray. (b) For the 15 patients with imaging-assessable tumor burden shown is a comparison of the tumor burden for the eight patients with no detected mutations compared to the seven patients with one or more mutations detected in plasma. The concordance rates for any mutations detected in plasma are shown immediately below the dot plot. Horizontal line indicates the median values
performed, and the concordance calculations are shown in Figure 3b .
Taken together, these results suggest that sensitivity and concordance of liquid biopsy-based variant detection in pretreated patients varies with tumor burden at the time of blood draw and that patients whose disease is well-controlled by treatment may have fewer or no detectable variants in plasma at a LOD of 1.0%. Further studies of concurrently collected, matched tissue will be necessary to more accurately assess plasma/tissue concordance.
| DISCUSSION
Liquid biopsies play an increasingly important role in the applica- small numbers of patients (Girotti et al., 2016; Gray et al., 2015; Tsao et al., 2015) . While these studies speak to the feasibility of liquid biopsy at diagnosis, a timepoint at which tissue biopsy is almost always simultaneously obtained, the question remains whether plasma NGS offers clinical utility once therapy has commenced. Here we describe the results of a pilot study utilizing a minimally adapted, commercially available ultra-deep sequencing platform to detect clinically relevant variants and monitor disease burden for patients with advanced melanoma.
While cfDNA is more frequently thought of as a means for identifying therapeutically targetable driver and resistance mutations, we and others have also shown that measuring the amount of cfDNA in plasma can be prognostic (Cargnin et al., 2017; Thompson et al., 2016) .
This may be especially relevant for our cohort of heavily pretreated patients, for whom mutations were detected in 12 of 25 plasma samples, but cfDNA yield was quantifiable for all 25 patients. Cell-free DNA yields were significantly associated with solid tumor burden as determined by imaging, suggesting that cfDNA may provide a blood-based means to monitor tumor burden more frequently than imaging. While our study was not designed to serially compare imaging-with bloodbased measurement of tumor volume, a larger study with concurrent imaging and blood collection could be utilized to assess whether cfDNA might better discern pseudoprogression or atypical response patterns from actual progression for patients receiving checkpoint inhibitors. Further studies could also assess whether cfDNA yield can accurately predict progression prior to imaging. Although additional studies would be required to validate the utility of cfDNA yield as a prognostic marker for patients with advanced melanoma, these pilot results suggest possible utility beyond detection of driver and resistance mutations.
For our study, we selected a plasma NGS panel encompassing full exon coverage for 61 genes. To be broadly clinically actionable, molecular monitoring of patients receiving targeted agents must go beyond the targeted loci to comprehensively detect associated resistance mutations. For instance, acquired resistance to the BRAF inhibitors vemurafenib and dabrafenib has been associated with multiple genetic alterations including mutations in NRAS, KRAS, MAP2K1, and CDKN2A (Shi et al., 2014) . In our study, 16 mutations were detected in eight different genes for 12 patients' plasma samples, including three patients with a detected BRAF V600E mutation. Two of these three patients received a BRAF inhibitor prior to blood draw, and the persistent detection of the targeted mutation suggests the targeted therapy may not be adequately controlling disease. Although no known resistance mutations were detected in the plasma of any of the patients who received a TKI, repeat liquid biopsies could be utilized for detection of such therapy resistance, just as we have previously demonstrated for lung cancer (Thompson et al., 2016) . This pilot study suggests that liquid biopsy detection of therapeutically targetable mutations is feasible for a pretreated population, although larger studies will be necessary to better define the clinical utility of this data.
To our knowledge, we describe here the first prospective study using an NGS panel of a broad set of cancer-relevant genes for analysis of plasma from patients with advanced melanoma who have received multiple prior therapies or are currently on therapy. Given the increasing number of targeted therapies being developed with relevance for melanoma patients and the approval of checkpoint inhibitors as standard of care, our gene panel will likely require expansion for the future management of patients with melanoma. While a baseline measurement of plasma-based BRAF V600 status alone has been shown to have prognostic value (Knol et al., 2016) , recent discoveries articulating the genomic heterogeneity underlying acquired resistance to BRAF inhibition speak to the need for monitoring of multiple loci over the course of a patient's therapy (Krepler et al., 2016; Shi et al., 2014) . Whole exome sequencing of paired baseline and relapse tissue samples for four patients with melanoma who had received pembrolizumab revealed resistance-associated mutations in JAK1, JAK2, and B2M (Zaretsky et al., 2016) . While JAK2 hotspots are covered on the tissue NGS panel utilized in our clinical lab, no mutations were detected in tissue for that gene, and these three genes are not covered by our current plasma panel. Tumor molecular burden, as assessed by whole exome sequencing of melanoma and other tumors (Rizvi et al., 2015; Van Allen et al., 2015) , has been associated with response to immune checkpoint inhibitors, suggesting that expanding the coverage of our 61-gene panel would enhance the clinical actionability of the ctDNA test for patient monitoring. It may also be desirable to improve the level of detection of this assay to detect mutations with an allele fraction in plasma of less than 1.0%. Tie and colleagues recently showed that detection of therapy resistance for patients with colorectal cancer by cfDNA can precede imaging by two or more months when using a sequencing-based approach with a sensitivity to detect variants at or below 0.01% allele fraction (Tie et al., 2016) . A similar report for patients with breast cancer utilized a highly sensitive digital PCR approach (Garcia-Murillas et al., 2015) .
While the tumor burden was either low or undetectable for our eight patients with available imaging and no detectable variants in plasma, our sensitivity of variant detection, especially in the context of minimal residual disease, may have been improved with a lower LOD. In summary, this proof of concept work demonstrates the feasibility of utilizing non-invasive, cfDNA-based molecular monitoring of patients with melanoma. Further study with larger prospective patient cohorts, and encompassing a range of timepoints over the course of the patients' disease, will be necessary to validate and firmly establish the clinical utility of this approach.
| METHODS
| Patients
This was 
| Blood sample collection and processing
Blood was drawn by conventional venipuncture into Streck DNA BCT tubes (Streck, Omaha, NE, USA) and processed for plasma collection within 36 hr of blood draw. In brief, the tubes were first spun at 1668 g for 10 min at room temperature. The supernatant was transferred to fresh 2 ml Eppendorf tubes without disturbing the cellular layer, and this plasma fraction was then centrifuged one or two additional times at 21,000 g for 10 min. Plasma samples were immediately transferred for storage at −80°C.
| Plasma DNA extraction and nextgeneration sequencing
Plasma samples were shipped overnight on dry ice to Illumina, Inc (San Diego, CA, USA). Cell-free DNA was extracted from 1 to 4 ml plasma per sample (see details in Table S3) (Table   S1 ) was evaluated by ultra-deep sequencing on an Illumina Next-Seq ® (Illumina, Inc), using protocols adapted from TruSeq Nano (Illumina, Inc) library preparation and Nextera Rapid Capture (Illumina, Inc) target enrichment (Janku et al., 2017) . Reads were mapped using hg19, and the LOD for detection of single nucleotide variants for sequencing of plasma-derived DNA was 1.0%. All cfDNA testing as described in this manuscript is for research use only, and not for use in diagnostic procedures.
| Tissue sample next-generation sequencing
Chart review was used to identify 22 patients who also had tissue sequenced at a previous timepoint during the course of their therapy. The elapsed time between tissue and plasma cfDNA sequencing ranged from 49 to 1,605 days (see Table S4 ). All tissue sequencing was conducted at the University of Pennsylvania Center for Personalized Diagnostics (CPD) CAP/CLIA-Certified laboratory as previously described (Hiemenz et al., 2016; Thompson et al., 2016; Yee et al., 2016) . For all but one patient, the Illumina TruSeq ® Amplicon-Cancer Panel (TSACP, FC-130-1008, Illumina, Inc) was used to sequence targeted hotspots or larger exonic regions for 47 genes (Table S5 ). One patient (1,368) had insufficient tissue DNA for the TSACP, so the sample was analyzed using the Penn Precision Panel for mutations in a smaller panel of 20 genes (Thompson et al., 2016) . Analysis of results for both panels was performed using a clinically validated informatics pipeline, using hg19 genome build to map reads (Daber, Sukhadia, & Morrissette, 2013) . The level of detection for sequencing of tissue was 4.0%.
| Bioinformatics and statistical analysis
Non-synonymous mutations were called from plasma-derived cfDNA if they met the following criteria: AF ≥1.0%, mean target coverage ≥300, and ≥2 mutant reads. These criteria have been previously validated as described (Janku et al., 2017) . In brief, DNA spiking experiments were used to assess the sensitivity, specificity, and negative and positive predictive value of the test at various sequence read thresholds, with optimal sensitivity for clinical samples achieved at a threshold of ≥2 unique variant sequence reads. Allele fraction is defined as the number of mutant reads divided by the number of total reads at a given locus.
Descriptive statistics were computed for study variables. 
